Pharma News

• Interim analysis of INPULSIS®-ON study shows: Beneficial effect of OFEV®* on slowing disease progression was maintained and the change from baseline in FVC was consistent over 2 years
  
• Long-term treatment with OFEV®* had a manageable safety and tolerability profile (mean exposure of 2.4 years, maximum exposure of more than 3 years)
  
• Commonly used concomitant medications, such as anti-acids or systemic steroids, do not influence the beneficial effect of OFEV®* on slowing disease progression
  

The U.S. Food and Drug Administration today approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar (glucose) control in adults with diabetes mellitus.

A new study suggests that the survival rate of premature babies born between 26 to 31 weeks of gestation can be improved by blocking light from reaching the intravenously-fed infused nutritious mixture for survival. The study was published in the Journal of Parenteral and Enteral Nutrition.

A new study suggests that sex does not lead to heart attack and also states that it is safe to engage in it, even after experiencing a heart attack. The research is published in the Journal of the American College of Cardiology.

Rice University Researchers reveal that Deep-diving whales may create synthetic blood. The study appears in the Journal of Biological Chemistry.

(NewsVoir); Necessity is the mother of all invention. Pharmaceuticals industry just got innovative in reaching out to doctors with the latest app for Apple Watch under the Ethical Marketing norms. Developed by Indegene, the leading provider of healthcare solutions to the global pharmaceuticals industry, medical insurers and hospitals in the US, has developed the latest app for the Apple Watch for the healthcare industry to engage with doctors. This app augurs well for the Pharma industry already reeling under pressures of compliance norms for ethical marketing to doctors.

Perrigo Company plc, received US Food and Drug Administration (FDA) approval for the generic version of Valeant Pharmaceutical International Inc's BenzaClin topical gel.

[adsense:336x280:8701650588]

Oculus Innovative Sciences, Inc., a specialty pharmaceutical company, introduce  two new MicrocynAH dermatology products for animals.

A new study has suggested that survivors of childhood brain tumors have lower working memory performance in adulthood compared to healthy adults. The study appeared in the Journal of the International Neuropsychological Society.